- Home
- / Fusion Pharmaceuticals
- / Financials
Header placeholder lorem ipsum dolor sit amet, consectetur adipiscing elit.
Fusion Pharmaceuticals financials data including stock price, CreditSafe score, income statement, balance sheet, and cash flow.
Revenue
$2.1 M
FY, 2023
CreditSafe Score
?
Score changed on Jun 07, 2026
Premium Content only available in Craft’s Intelligence Portal
View 30+ financial ratio metrics including price-to-earnings ratio, debt-to-assets ratio, gross profit margin, and more.
Financial ratio metrics help evaluate the financial strength of a company, and help raise red flags that can indicate potential risk, fulfillment challenges, or even possible bankruptcy.
Learn moreFinancial Statements
| USD | FY, 2020 | FY, 2021 | FY, 2022 | FY, 2023 |
|---|---|---|---|---|
| Revenue | 1.4M | 1.5M | 2.1M | |
| Gross profit | 1.4M | 1.5M | 2.1M | |
| Gross profit margin, % | 100.0% | 100.0% | 100.0% | |
| Operating expense total | 76.6M | 82.8M | 88.6M | 100.0M |
| Depreciation and amortization | 482.0K | 634.0K | 909.0K | 1.3M |
| EBITDA | (76.6M) | (81.4M) | (87.1M) | (97.9M) |
| EBITDA margin, % | -5651.5% | -5963.4% | -4733.4% | |
| EBIT | (76.0M) | (81.5M) | (89.8M) | (98.5M) |
| EBIT margin, % | -5662.9% | -6147.1% | -4761.6% | |
| Interest income | 327.0K | 381.0K | 2.2M | 9.5M |
| Interest expense | 1.8M | 5.2M | ||
| Pre tax profit | (75.7M) | (81.2M) | (89.4M) | (94.1M) |
| Income tax expense | 2.6M | (118.0K) | (1.8M) | 787.0K |
| Net Income | (78.3M) | (81.0M) | (87.6M) | (94.9M) |